IN THE SPOTLIGHT

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Single-cell atlas reveals a pro-metastatic RELB+ neutrophil-myeloid subset underlying lymph node metastasis in EGFR-wildtype LUAD

Single-cell atlas reveals a pro-metastatic RELB+ neutrophil-myeloid subset underlying lymph node metastasis in EGFR-wildtype LUAD

Structure-based discovery of Ginkgo biloba derived inhibitors of EGFR: a multi-scale computational method for cancer therapy

Structure-based discovery of Ginkgo biloba derived inhibitors of EGFR: a multi-scale computational method for cancer therapy

Association between thoracic CT scan findings and EGFR mutation subtypes in patients with pulmonary adenocarcinoma

Association between thoracic CT scan findings and EGFR mutation subtypes in patients with pulmonary adenocarcinoma

Dana-Farber Cancer Institute Inc Files Patent Application for Mutant-Selective EGFR Inhibitors

Dana-Farber Cancer Institute Inc Files Patent Application for Mutant-Selective EGFR Inhibitors

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer

Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial

Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial